Dupilumab as a combination therapy to oral systemic immunomodulators for moderate-to-severe atopic dermatitis for skin of color children in resource-limited setting: A case series
Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poo...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
Call Number: |
A1234.567 |
---|---|
Copy 1 | Available |